Quality of life of patients with inflammatory bowel disease using immunobiological therapy

Journal of Coloproctology - Tập 39 - Trang 107-114 - 2019
Raphael Souza de Almeida1, Ana Carolina Ribeiro Lisboa1, Alex Rodrigues Moura1
1Universidade Federal de Sergipe (UFS), Departamento de Medicina, Aracaju, SE, Brazil

Tóm tắt

Abstract Objectives To assess the quality of life of patients diagnosed with inflammatory bowel disease (IBD) using immunobiological therapy and to relate the general and domain scores of the Inflammatory Bowel Disease Questionnaire (IBDQ) to the immunobiological drug in use and the clinical and sociodemographic variables. Methods This was a descriptive observational cross-sectional study, conducted from June to September 2018 in a tertiary hospital in Sergipe, which included 47 patients with a diagnosis of Crohn's disease. The IBDQ questionnaire was applied together with a sociodemographic questionnaire, and the clinical data and the history of the disease were analyzed. Results Female, mixed-race, married patients from the countryside of the state of Sergipe, Brazil, who had never undergone any intestinal surgery, represented most of the study participants. 24 patients were on infliximab and 23 were on adalimumab. Variables such as gender, type of immunobiological drug and duration of its use, and association of therapy with other medications were shown to statistically significantly influence the report quality of life (p-value < 0.05). Conclusion Further studies with larger samples are necessary to allow a more accurate delimitation of the impact of clinical and sociodemographic variables on the quality of life of patients with inflammatory bowel disease.

Tài liệu tham khảo

Hanauer, 2006, Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities, Inflamm Bowel Dis, 3, 10.1097/01.MIB.0000195385.19268.68 Loftus, 2004, Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences, Gastroenterology, 126, 1504, 10.1053/j.gastro.2004.01.063 Pillai, 2017, A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease, PLOS ONE, 12, 1, 10.1371/journal.pone.0185500 Etchevers, 2010, Optimizing the use of tumour necrosis factor inhibitors in Crohns disease: a practical approach, Drugs [Internet], 70, 109, 10.2165/11533700-000000000-00000 WHO, 1998, WHOQOL: measuring quality of life, Psychol Med [Internet], 28, 551 De Souza, 2004, Qualidade de vida de pacientes portadores de doença inflamatória intestinal, Arq Gastroenterol, 41, 137 Casellas, 2001, Influence of inflammatory bowel disease on different dimensions of quality of life, Eur J Gastroenterol Hepatol, 13, 567, 10.1097/00042737-200105000-00017 Stange, 2006, European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis, Gut [Internet], 55, i1 Zhou, 2010, Assessing health-related quality of life in patients with inflammatory bowel disease in Zhejiang China, J Clin Nurs, 19, 79, 10.1111/j.1365-2702.2009.03020.x Pontes, 2004, Qualidade de vida em pacientes portadores de doença inflamatória intestinal: tradução para o português e validação do questionário Inflammatory Bowel Disease Questionnaire (IBDQ), Arq Gastroenterol, 41, 137, 10.1590/S0004-28032004000200014 Lichtenstein, 2002, Infliximab improves quality of life in patients with Crohn’ s Disease, Inflamm Bowel Dis, 8, 237, 10.1097/00054725-200207000-00001 Baumgart, 2007, Inflammatory bowel disease: clinical aspects and established and evolving therapies, Lancet, 369, 1641, 10.1016/S0140-6736(07)60751-X Ministério da Saúde. Secretaria de Ciência Tecnologia e Insumos Estratégicos. Departamento de Gestão e Incorporação de Tecnologias em Saúde. Infliximabe para o tratamento da Retocolite Ulcerativa Grave refratária a corticoides e ciclosporina. Relatório Recom da Comissão Nac Inc Tecnol no SUS – CONITEC – 105 [Internet]. 2014;22. Ministério da Saúde, 2013, 9 Lichtiger, 2010, The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohns disease who failed prior infliximab therapy, Aliment Pharmacol Ther, 32, 1228, 10.1111/j.1365-2036.2010.04466.x Colombel, 2010, Infliximab, azathioprine, or combination therapy for Crohn's disease, N Engl J Med, 362, 1383, 10.1056/NEJMoa0904492 Xu, 2014, Different therapeutic approaches on quality of life in patients with inflammatory bowel disease, BMC Gastroenterol, 14, 1, 10.1186/s12876-014-0199-5 Conejero, 2014, Gender differences in emotions, forgiveness and tolerance in relation to political violence, Span J Psychol, e9, 10.1017/sjp.2014.9 Ministério da Saúde, 2017 Singh, 2014, Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis, Mayo Clin Proc, 89, 1621, 10.1016/j.mayocp.2014.08.019 Stidham, 2014, Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease, Aliment Pharmacol Ther, 39, 1349, 10.1111/apt.12749 Casellas, 2012, Restoration of quality of life of patients with inflammatory bowel disease after one year with antiTNFα treatment, J Crohn's Colitis [Internet], 6, 881, 10.1016/j.crohns.2012.01.019
Thông tin
Thông tin xuất bản

Journal of Coloproctology

Tập 39

107-114

Thông tin tác giả